Intellia Therapeutics (NTLA) Earnings Analysis

Intellia Therapeutics (NTLA) next reports earnings on 2026-08-06, consensus EPS -0.8 USD. Last quarter (2026-05-11) it beat with EPS -0.81 USD vs -0.92 USD est (+12%). It has beaten estimates in 5/6 recent quarters (83%). Trailing P/E -3.14.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does NTLA next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.8 USD
Revenue estimate0.01B

NTLA earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-11-0.81 USD-0.92 USD+12%Beat
2026-02-26-0.83 USD-0.99 USD+16.2%Beat
2025-11-06-0.92 USD-1.02 USD+9.8%Beat
2025-05-08-1.1 USD-1.26 USD+12.7%Beat
2025-02-27-1.24 USD-1.32 USD+6.1%Beat
2024-08-08-1.31 USD-1.21 USD-8.3%Miss

Beat rate: 5/6 (83%) over reported quarters with consensus data.

NTLA valuation and analyst view

Trailing P/E-3.14
Trailing EPS-3.33021 USD
Price / book2.12
Dividend yield0.00%
Market cap1.25B
Analyst consensusBuy (28 buy / 8 hold / 3 sell)
Avg price target23.33 USD

Related research pages

Frequently asked questions

When is Intellia Therapeutics (NTLA)'s next earnings date?

Intellia Therapeutics is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.8 USD and revenue estimate of 0.01B.

Did NTLA beat earnings last quarter?

In its 2026-05-11 report, NTLA posted EPS of -0.81 USD versus a -0.92 USD estimate — a beat of 12%.

What is NTLA's earnings track record?

Over the last 6 reported quarters with consensus data, NTLA beat estimates 5 times (83%).

What is NTLA's current P/E ratio and EPS?

NTLA trades at a trailing P/E of -3.14 on trailing EPS of -3.3302050805975187 USD.

What do analysts rate NTLA?

Analyst consensus is "Buy" across 39 ratings (0 strong buy, 28 buy, 8 hold, 3 sell, 0 strong sell). Average 12-month price target: 23.33 USD.